quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·35d
PRRelease
PLUS THERAPEUTICS Inc. logo

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

PSTV· PLUS THERAPEUTICS Inc.
Health Care
Original source

Companies

  • PSTV
    PLUS THERAPEUTICS Inc.
    Health Care

Recent analyst ratings

  • Feb 3UpdateLake Street$2.00
  • Sep 3UpdateD. Boral Capital$5.00
  • Mar 17UpdateD. Boral Capital$9.00

Related

  • PR19h
    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
  • INSIDER1d
    SEC Form 4 filed by Daniels Eric Joseph
  • PR1d
    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER2d
    SEC Form 3 filed by new insider Daniels Eric Joseph
  • SEC2d
    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR2d
    Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
  • PR8d
    Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
  • SEC14d
    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022